Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Maximus accepts both HSA and FSA cards for weight loss treatment
This is higher than other GLP-1s, which had discontinuation rates of 6.1% (tirzepatide), 8.0% (semaglutide) and 10.3% (orforglipron)
Although retatrutide may be more effective than weight loss drugs currently on the market, it is not available right now
It is unknown whether Zepbound causes thyroid C-cell tumors in humans
The Chinese government's 14th Five-Year Plan for healthcare specifically identifies diabetes management as a chronic disease prevention priority, with investment in guideline-based pharmacotherapy programs that are driving adoption of evidence-based GLP-1 therapy in public healthcare settings Middle East & Africa and Latin America GLP-1 Receptor Agonist Market Insights The Middle East represents a commercially interesting GLP-1 market because the Gulf states combine high rates of type 2 diabetes and obesity the UAE's adult obesity rate exceeds 37%, among the world's highest with high-income consumer populations and expanding private health insurance coverage
[PMID: 15465007] PubMed record related to this compound for laboratory literature review
US$ 26.13
US$ 29.55
US$ 21.48
US$ 26.28
